What is HC Wainwright’s Forecast for BEAM Q1 Earnings?

Beam Therapeutics Inc. (NASDAQ:BEAM) – Stock analysts at HC Wainwright issued their Q1 2027 earnings per share estimates for Beam Therapeutics in a research note issued on Monday, March 2nd. HC Wainwright analyst P. Trucchio expects that the company will post earnings of ($0.90) per share for the quarter. The consensus estimate for Beam Therapeutics’ current full-year earnings is ($4.57) per share. HC Wainwright also issued estimates for Beam Therapeutics’ Q2 2027 earnings at ($0.90) EPS, Q3 2027 earnings at ($0.85) EPS, Q4 2027 earnings at ($0.87) EPS and FY2030 earnings at ($1.37) EPS.

Beam Therapeutics (NASDAQ:BEAM) last issued its quarterly earnings results on Tuesday, February 24th. The company reported $2.33 EPS for the quarter, beating analysts’ consensus estimates of ($1.13) by $3.46. Beam Therapeutics had a negative return on equity of 30.65% and a negative net margin of 57.24%.The firm had revenue of $114.11 million during the quarter, compared to the consensus estimate of $13.22 million. During the same quarter in the prior year, the business posted ($1.09) earnings per share. Beam Therapeutics’s revenue for the quarter was up 280.3% on a year-over-year basis.

Several other analysts have also recently issued reports on BEAM. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Beam Therapeutics in a report on Wednesday, January 21st. Sanford C. Bernstein boosted their target price on shares of Beam Therapeutics from $37.00 to $41.00 and gave the stock an “outperform” rating in a research report on Tuesday, January 20th. Evercore started coverage on shares of Beam Therapeutics in a research report on Monday, November 24th. They set an “outperform” rating and a $35.00 price target on the stock. Tudor Pickering set a $41.00 price target on Beam Therapeutics in a research note on Wednesday, January 21st. Finally, UBS Group began coverage on Beam Therapeutics in a research note on Wednesday, January 7th. They set a “neutral” rating and a $28.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $46.19.

Beam Therapeutics Stock Down 5.1%

Shares of BEAM opened at $27.22 on Wednesday. The firm has a market cap of $2.77 billion, a price-to-earnings ratio of -26.95 and a beta of 2.12. The business’s 50 day moving average is $28.92 and its two-hundred day moving average is $25.39. Beam Therapeutics has a 52-week low of $13.52 and a 52-week high of $36.44.

Institutional Trading of Beam Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. Bank Julius Baer & Co. Ltd Zurich acquired a new position in Beam Therapeutics during the 4th quarter valued at approximately $47,000. Larson Financial Group LLC lifted its stake in Beam Therapeutics by 4,370.5% in the third quarter. Larson Financial Group LLC now owns 1,967 shares of the company’s stock valued at $48,000 after buying an additional 1,923 shares during the last quarter. Kestra Advisory Services LLC acquired a new position in shares of Beam Therapeutics during the fourth quarter valued at $59,000. Van ECK Associates Corp grew its position in shares of Beam Therapeutics by 48.7% during the third quarter. Van ECK Associates Corp now owns 2,158 shares of the company’s stock worth $52,000 after acquiring an additional 707 shares during the last quarter. Finally, Leonteq Securities AG bought a new position in shares of Beam Therapeutics during the fourth quarter worth about $66,000. 99.68% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Beam Therapeutics

In related news, insider Christine Bellon sold 1,371 shares of the stock in a transaction dated Thursday, January 22nd. The shares were sold at an average price of $34.00, for a total transaction of $46,614.00. Following the sale, the insider owned 95,667 shares in the company, valued at $3,252,678. This represents a 1.41% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 3.50% of the stock is currently owned by corporate insiders.

Beam Therapeutics Company Profile

Beam Therapeutics, Inc (NASDAQ: BEAM) is a biotechnology company dedicated to developing precision genetic medicines through its pioneering base editing platform. Headquartered in Cambridge, Massachusetts, with additional research facilities in Philadelphia, the company focuses on engineering molecular editors capable of making precise single-nucleotide changes in DNA. By harnessing its proprietary base editing technology, Beam aims to correct or disrupt disease-causing genetic variants at their source, offering the potential for novel therapies in areas with significant unmet medical need.

Founded in 2017 as a spin-out from Harvard University and the Broad and Whitehead Institutes, Beam was co-founded by leading academic researcher David R.